Interviews, Articles & Podcasts
Can Cell Therapy Reverse Hearing Loss?
Brian Taylor, AuD of This Week in Hearing speaks with Lineage CEO Brian Culley about the ReSonance™ Program
January 6, 2025
Revolutionizing Medicine with Cell Therapy
Solomon Wilcots of Russo partners speaks with Lineage CEO Brian Culley
October 16, 2024
BioTech Nation … with Dr. Moira Gunn
Brian Culley, CEO, talks about a new approach to treating diseases which replaces damaged cells with new ones.
October 16, 2024
Labiotech
CEO Brian Culley discusses the OPC1 program and the challenges associated with clinical trials in the SCI space
October 7, 2024
BioTechTV
CEO Brian Culley describes the idea behind organizing the Spinal Cord Injury Investor Symposium and gives an overview of Lineage’s cell therapy approach
June 26, 2024
Business of BioTech
CEO Brian Culley met with @mattpillar on the Business of Biotech Podcast to share insights into our spinal cord injury program and our journey of innovation and resilience.
June 24, 2024
Presentations from specific events, conferences, or showcases
Key opinion leaders discuss topics related to Lineage’s clinical programs
Richard Fessler, MD, Professor of Neurosurgery, Rush University Medical School, discusses data seen in the phase 1/2 clinical trial of OPC1 for spinal cord injury (watch on CGTLive.com)
July 20, 2022
Review of the pathogenesis of AMD and the pathways to CNV and GA
Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, Barcelona Macula Foundation
OpRegen® Phase 1/2a Clinical Study Results
2020 ARVO Meeting
Christopher D. Riemann, M.D., Cincinnati Eye Institute (CEI)
Why is dry age-related macular degeneration (dry AMD) research so important?
Allen C. Ho, M.D., Wills Eye Hospital Director of Retina Research
Why is spinal cord research so important?
Dr. John Steeves, Emeritus Principal Investigator @ICORD and Professor @UBC
A selection of patient focused media related to our cell therapy programs
The Stem Cellar
The Official Blog of CIRM, California’s Stem Cell Agency
Where Are They Now: Jake Javier
Pioneering Cell Transplants for the Treatment of Spinal Cord Injury
Christopher and Dana Reeve Foundation Blog
OPC1 Patient Spotlight – Chris Block – Part 1
In 2016, Chris Block was paralyzed in a bicycling accident. In 2023, he is an avid scuba diver, horseback rider and, importantly, has his independence.
OPC1 Patient Spotlight – Chris Block – Part 2
In 2016, Chris Block was paralyzed in a bicycling accident. In 2023, he is an avid scuba diver, horseback rider and, importantly, has his independence.
The Stem Cellar
The Official Blog of CIRM, California’s Stem Cell Agency
Update on spinal cord injury patient Jake Javier, enrolled in CIRM-funded stem cell clinical trial
OPC1 Program – Patient Spotlight – Jake Javier
In 2016, Jake Javier was paralyzed from the neck down. In late 2022, he is set to graduate from Duke University with his Master’s Degree in Biomedical Engineering, with plans to help those impacted by neurological injuries or diseases.
Sonia Cohen’s OpRegen Story
OpRegen for Dry AMD | Lineage Cell Therapeutics
Cheri’s Story
OpRegen for Dry AMD | Lineage Cell Therapeutics
WDAM7 Mississippi
“New Treatment for Age-Related Dry Macular Degeneration”
5 years through the eyes of a mum.
A powerful dramatization of living with the progression of vision loss related to AMD. Source: www.macularsociety.org
Spinal Cord Injury and Lineage’s OPC1 Cell Therapy
An instructive whiteboard video explaining how spinal cord injury disrupts normal bodily function as well as OPC1 administration and mechanism of action.
OPC1 Program – Patient Spotlight – Kris Boesen and Lucas Lindner
Highlighting the progress made by Kris Boesen and Lucas Lindner, both of whom received Lineage’s OPC1 cell therapy following traumatic spinal cord injury (SCI).
Lucas Lindner was paralyzed from the neck down following a car accident. The next year, he threw out the first pitch at a Major League Baseball game.
Watch the video above to learn more about Lucas’ journey.